MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2018 International Congress

    Long Term Response to L-dopa in Parkinson Disease

    H. Gupta, N. Wachter, K. Lyons, R. Pahwa (Kansas, KS, USA)

    Objective: To assess the long-term effectiveness of levodopa in Parkinson’s disease (PD) patients. Background: To date, levodopa continues to be the most efficacious drug in…
  • 2018 International Congress

    Objective Predictors of ‘Early Tolerance’ to Ventral Intermediate nucleus of thalamus DBS In Essential Tremor Patients

    S. Merchant, S. Kuo, S. Pullman, B. Ford (Bethesda, MD, USA)

    Objective: To identify pre-operative clinical and computerized spiral analysis characteristics that may help ascertain which patients with Essential Tremor (ET) will exhibit ‘early tolerance’ to…
  • 2018 International Congress

    Integrated Complimentary Yoga and Ayurveda Treatment Confers Significant Benefits in PD Patients

    H. Babu, U. Kumbhare, T. Raju, N. R, N. R (Bengaluru, India)

    Objective: The present study was carried out to evaluate the efficacy of integrated complimentary Yoga & Ayurveda treatment in improving the motor symptoms and also…
  • 2018 International Congress

    Variation in the L-dopa motor response in pathologically confirmed Parkinson’s disease

    V. Pitz, N. Malek, K. Grosset, D. Grosset (Glasgow, United Kingdom)

    Objective: To examine the L-dopa-response (improvement in motor symptoms) in published cases of pathologically confirmed Parkinson’s disease (PD). Background: L-dopa responsiveness supports the diagnosis of…
  • 2018 International Congress

    Clinical effectiveness of a highly challenging balance training (HiBalance program) for Parkinson’s disease: A multi-center clinical effectiveness trial

    B. Leavy, C. Joseph, N. Löfgren, H. Johansson, M. Hagströmer, E. Franzén (Stockholm, Sweden)

    Objective: To determine the effectiveness of the adapted HiBalance program on balance control and gait among people with mild-moderate PD when performed in multiple clinical…
  • 2018 International Congress

    Effect of COMT-inhibitor in the clinical progression of Parkinson’s disease

    I.U. Song, K.S. Lee, Y.A. chung (Incheon, Republic of Korea)

    Objective: We conducted this 2-year follow-up study to evaluate whether or not catechol-O-methyltransferase inhibitor (COMTI) has an impact on the progression or severity of Parkinson's…
  • 2018 International Congress

    Effects of rTMS on three cortical areas in Parkinson’s Disease

    V. Goyal, P. Bhat, C. Goyal, A. Srivastava, S. Kumaran, M. Behari, S. Dwivedi (Delhi, India)

    Objective: To evaluate the role of rTMS over primary motor area, premotor area, supplementary motor area in Parkinsons Disease. Background: Parkinson’s disease (PD) presents with…
  • 2018 International Congress

    Objective analysis of walking tremor in Parkinson’s disease: A spectrum of classical rest tremor?

    N. Dadphan, O. Jitkritsadakul, C. Anan, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To delineate objective characteristics of walking tremor in PD patients in relation to classical parkinsonian rest tremor with inertial sensors. Background: Tremors in PD…
  • 2018 International Congress

    Switching from double-blind entacapone or placebo to open-label opicapone: NMSS results of the 1-year extension BIPARK-I study

    O. Fabregues, E. Tolosa, J. Ferreira, A. Lees, A. Santos, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Barcelona, Spain)

    Objective: To evaluate the impact on non-motor symptoms in levodopa-treated Parkinson’s disease (PD) patients who switched from placebo (PLC) or entacapone (ENT) to opicapone (OPC)…
  • 2018 International Congress

    Putative treatment of Parkinson’s Disease using extract of Bacopa monnieri

    S. Sinha, P. Kumar (Allahabad, India)

    Objective: Bacopa monnieri is largely treasured as a revitalizing herb used by Ayurvedic medical practitioners for almost 3000 years. The herb has been mentioned in…
  • « Previous Page
  • 1
  • …
  • 49
  • 50
  • 51
  • 52
  • 53
  • …
  • 177
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley